Jay Olson

We're curious about the VESALIUS-CV results and how you expect them to impact the overall market opportunity for Repatha?

Can you provide some color on the time line to file for approval, especially with regards to the results for -- from FORTITUDE-102, do you need those for filing?

Can you help us understand what to expect on the Bemarituzumab Phase III study readout coming up here in the second quarter?

Could you describe the key lessons you expect to learn from the Repatha VESALIUS-CV outcome study results, how you can leverage those lessons across your portfolio

how do you expect the subcu version to further impact treatment persistence

Can you talk about the level of expense that you're investing in Lycanby

How large is the incremental patient population you can address with subcu? And is there an opportunity for a direct-to-consumer education about subcu LEQEMBI

can you share your thoughts on the trial design and how are you viewing the competitive landscape that's evolving in PDAC

Can you describe the rationale behind terminating the BET inhibitor program? Was that mostly related to your strategic focus on targeted therapies

Can you just share with us your thoughts on the relative importance of the 3 therapeutic areas at Incyte oncology, hematology, immunology

what are the key data points we should be looking out for in your ASCO update and what are the gating factors to starting the phase three study

Can you just talk about your plans to commercialize rux XR and also the timeline for a fixed-dose combination with your BET inhibitor?